Marek Ancukiewicz

19.3k total citations · 6 hit papers
127 papers, 11.8k citations indexed

About

Marek Ancukiewicz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Marek Ancukiewicz has authored 127 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 30 papers in Surgery. Recurrent topics in Marek Ancukiewicz's work include Glioma Diagnosis and Treatment (16 papers), Angiogenesis and VEGF in Cancer (14 papers) and Advanced Radiotherapy Techniques (12 papers). Marek Ancukiewicz is often cited by papers focused on Glioma Diagnosis and Treatment (16 papers), Angiogenesis and VEGF in Cancer (14 papers) and Advanced Radiotherapy Techniques (12 papers). Marek Ancukiewicz collaborates with scholars based in United States, France and Australia. Marek Ancukiewicz's co-authors include Rakesh K. Jain, Herman D. Suit, Bruce Thompson, Jay S. Loeffler, Dan G. Duda, Andrzej Niemierko, Harald Paganetti, Michael Goitein, Leo E. Gerweck and Christopher G. Willett and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Marek Ancukiewicz

125 papers receiving 11.5k citations

Hit Papers

Relative biological effectiveness (RBE) values for proton... 2000 2026 2008 2017 2002 2006 2012 2000 2011 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Relative biological effectiveness (RBE) values for proton beam therapy
    2002 1.1k citations Marek Ancukiewicz, Jay S. Loeffler et al. profile →
  2. Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome
    2006 943 citations Paul N. Lanken, Robert C. Hyzy et al. profile →
  3. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
    2012 828 citations Yuhui Huang, Marek Ancukiewicz et al. profile →
  4. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    2000 551 citations Emmanuelle di Tomaso, Marek Ancukiewicz et al. profile →
  5. Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
    2011 548 citations Marek Ancukiewicz, Jeffrey W. Clark et al. profile →
  6. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*
    2005 547 citations Polly E. Parsons, Mark D. Eisner et al. Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marek Ancukiewicz United States 47 4.3k 3.3k 2.4k 2.1k 2.0k 127 11.8k
Lois B. Travis United States 62 3.4k 0.8× 4.8k 1.5× 1.7k 0.7× 2.5k 1.2× 1.6k 0.8× 183 14.0k
Éric Deutsch France 56 3.5k 0.8× 4.3k 1.3× 3.0k 1.2× 1.7k 0.8× 1.4k 0.7× 584 12.9k
Rochelle E. Curtis United States 53 2.2k 0.5× 4.3k 1.3× 1.1k 0.4× 1.7k 0.8× 1.3k 0.6× 109 11.2k
Wilfried Budach Germany 51 4.5k 1.0× 2.7k 0.8× 1.8k 0.7× 3.6k 1.7× 1.8k 0.9× 334 10.4k
Volker Budach Germany 49 4.6k 1.1× 3.5k 1.1× 1.5k 0.6× 2.6k 1.3× 1.1k 0.6× 395 12.3k
Alan Horwich United Kingdom 45 5.6k 1.3× 2.6k 0.8× 2.0k 0.8× 2.4k 1.2× 1.5k 0.8× 140 10.4k
Danny Rischin Australia 56 6.2k 1.4× 7.8k 2.4× 3.1k 1.3× 3.0k 1.4× 2.2k 1.1× 369 15.4k
Beow Y. Yeap United States 68 10.3k 2.4× 7.1k 2.2× 3.1k 1.3× 1.3k 0.6× 2.2k 1.1× 206 14.4k
Rainer Fietkau Germany 50 2.1k 0.5× 3.8k 1.1× 1.4k 0.6× 2.6k 1.3× 1.2k 0.6× 480 9.9k
Stuart A. Grossman United States 63 3.6k 0.8× 4.5k 1.4× 2.8k 1.1× 1.3k 0.6× 1.7k 0.9× 346 14.4k

Countries citing papers authored by Marek Ancukiewicz

Since Specialization
Citations

This map shows the geographic impact of Marek Ancukiewicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Ancukiewicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Ancukiewicz more than expected).

Fields of papers citing papers by Marek Ancukiewicz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Ancukiewicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Ancukiewicz. The network helps show where Marek Ancukiewicz may publish in the future.

Co-authorship network of co-authors of Marek Ancukiewicz

This figure shows the co-authorship network connecting the top 25 collaborators of Marek Ancukiewicz. A scholar is included among the top collaborators of Marek Ancukiewicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marek Ancukiewicz. Marek Ancukiewicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Malley, David M., Ana Oaknin, Bradley J. Monk, et al.. (2021). Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecologic Oncology. 163(2). 274–280. 79 indexed citations
2.
Zhu, Andrew X., Richard S. Finn, Mary F. Mulcahy, et al.. (2013). A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research. 19(23). 6614–6623. 122 indexed citations
3.
Zhu, Andrew X., Marek Ancukiewicz, Jeffrey G. Supko, et al.. (2013). Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Clinical Cancer Research. 19(6). 1557–1566. 55 indexed citations
4.
Lu‐Emerson, Christine, Matija Snuderl, Nathaniel D. Kirkpatrick, et al.. (2013). Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology. 15(8). 1079–1087. 177 indexed citations
5.
Sahani, Dushyant V., Tao Jiang, Koichi Hayano, et al.. (2013). Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. Journal of Hematology & Oncology. 6(1). 51–51. 42 indexed citations
6.
Sorensen, A. Gregory, Kyrre E. Emblem, Pavlina Polaskova, et al.. (2011). Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion. Cancer Research. 72(2). 402–407. 241 indexed citations
7.
Liu, Kathleen D., Bruce Thompson, Marek Ancukiewicz, et al.. (2011). Acute kidney injury in patients with acute lung injury: Impact of fluid accumulation on classification of acute kidney injury and associated outcomes*. Critical Care Medicine. 39(12). 2665–2671. 250 indexed citations
8.
Zhu, Andrew X., Dan G. Duda, Marek Ancukiewicz, et al.. (2010). Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value. Clinical Cancer Research. 17(4). 918–927. 25 indexed citations
9.
Batchelor, Tracy T., Dan G. Duda, Emmanuelle di Tomaso, et al.. (2010). Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology. 28(17). 2817–2823. 406 indexed citations
10.
Sorensen, A. Gregory, Tracy T. Batchelor, Weiting Zhang, et al.. (2009). A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Research. 69(13). 5296–5300. 291 indexed citations
11.
Cooke, Colin R., Chirag V. Shah, Robert Gallop, et al.. (2009). A simple clinical predictive index for objective estimates of mortality in acute lung injury*. Critical Care Medicine. 37(6). 1913–1920. 42 indexed citations
12.
Gaissert, Henning A., Cameron D. Wright, Marek Ancukiewicz, et al.. (2009). POINT: Operative risk of pneumonectomy—Influence of preoperative induction therapy. Journal of Thoracic and Cardiovascular Surgery. 138(2). 289–294. 22 indexed citations
13.
Arroliga, Alejandro C., Bruce Thompson, Marek Ancukiewicz, et al.. (2008). Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome*. Critical Care Medicine. 36(4). 1083–1088. 79 indexed citations
14.
Erickson, Sara E., Michael G. Shlipak, Greg S. Martin, et al.. (2008). Racial and ethnic disparities in mortality from acute lung injury*. Critical Care Medicine. 37(1). 1–6. 129 indexed citations
15.
Xu, Ling, Emmanuelle DiTomaso, Yves Boucher, et al.. (2008). Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC). Journal of Clinical Oncology. 26(15_suppl). 4096–4096. 2 indexed citations
16.
Parikh, Chirag R., Edward Abraham, Marek Ancukiewicz, & Charles L. Edelstein. (2005). Urine IL-18 Is an Early Diagnostic Marker for Acute Kidney Injury and Predicts Mortality in the Intensive Care Unit. Journal of the American Society of Nephrology. 16(10). 3046–3052. 409 indexed citations
17.
Parsons, Polly E., Mark D. Eisner, Bruce Thompson, et al.. (2005). Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*. Critical Care Medicine. 33(1). 1–6. 547 indexed citations breakdown →
18.
Leval, Laurence de, Kristina Braaten, Marek Ancukiewicz, et al.. (2003). Diffuse Large B-Cell Lymphoma of Bone. The American Journal of Surgical Pathology. 27(9). 1269–1277. 47 indexed citations
19.
Samsa, Greg, et al.. (1997). Assessing Uncertainty in Cost-Effectiveness Analyses. Medical Decision Making. 17(4). 390–401. 42 indexed citations
20.
Heinle, Sheila K., et al.. (1993). Usefulness of dobutamine echocardiography for detecting restenosis after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology. 72(17). 1220–1225. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lois B. Travis Breakdown of academic impact, for papers by Éric Deutsch Breakdown of academic impact, for papers by Rochelle E. Curtis Breakdown of academic impact, for papers by Wilfried Budach Breakdown of academic impact, for papers by Volker Budach Breakdown of academic impact, for papers by Alan Horwich Breakdown of academic impact, for papers by Danny Rischin Breakdown of academic impact, for papers by Beow Y. Yeap Breakdown of academic impact, for papers by Rainer Fietkau Breakdown of academic impact, for papers by Stuart A. Grossman
Rankless by CCL
2026